Atossa Therapeutics, Inc. (ATOS)

Over the past six months, Atossa Therapeutics' stock price has generally declined, decreasing approximately 28.55%. The share price as of January 9, 2026, was $0.65, down from $0.92 on January 13, 2025. Atossa Therapeutics received a "Study May Proceed" letter from the FDA for its (Z)-Endoxifen Investigational New Drug Application for metastatic breast cancer on January 6, 2026. On December 17, 2025, the company won the 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy Category for its work on (Z)-endoxifen. Atossa Therapeutics presented four clinical trial updates highlighting (Z)-Endoxifen research at the 2025 San Antonio Breast Cancer Symposium on December 15, 2025. On November 12, 2025, Atossa reported its Third Quarter 2025 financial results and provided a corporate update. In October 2025, the company amended its Phase 2 EVANGELINE study of (Z)-endoxifen and highlighted progress in its RECAST™ DCIS platform trial. On August 12, 2025, Atossa announced its Second Quarter 2025 financial results, noting positive FDA feedback clearing the path for an IND filing for (Z)-Endoxifen in metastatic breast cancer and strong I-SPY2 results.

Demand seasonality for Atossa Therapeutics primarily refers to the seasonality observed in its stock performance rather than direct product demand. Historical data suggests that buying ATOS stock in April has the highest probability of a positive return, while November has the lowest probability.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology, particularly breast cancer, and also has programs for other breast conditions and COVID-19. Their lead drug candidate is oral (Z)-endoxifen, in Phase II clinical trials for breast cancer treatment and prevention, and is also being evaluated for Duchenne Muscular Dystrophy. Additionally, they are developing AT-H201, an inhaled therapy for hospitalized COVID-19 patients, and AT-301, a nasal spray for at-home use by COVID-19 patients.

Atossa Therapeutics, Inc. is headquartered in Seattle, Washington, United States, which serves as the company's main operational hub.

In the past year, Atossa Therapeutics has received positive recognition for its scientific advancements, including the 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category for its work on (Z)-endoxifen.

Atossa Therapeutics, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Approximately 15.00% of the company's stock is held by institutional shareholders, 11.04% by Atossa Therapeutics insiders, and 73.96% by retail investors. Major institutional owners include Vanguard Group Inc., Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), Ameriprise Financial Inc., BlackRock, Inc., Millennium Management Llc, Renaissance Technologies Llc, Geode Capital Management, Llc, and Fidelity Extended Market Index Fund (FSMAX). The largest individual Atossa Therapeutics shareholder is Shuchih Chen, who owns 9.10 million shares, representing 7.04% of the company.